Navigation Links
TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Date:9/10/2007

ivary flow were detected for NGX267 in comparison to placebo. These effects increased linearly with dose, were maintained over four days of dosing, and within subject peak increases in salivary flow correlated with peak plasma levels of NGX267.

Decreased salivary flow results in dry mouth, or xerostomia, and is a symptom of a number of underlying conditions. Causes of dry mouth include the autoimmune disorder Sjogren's Syndrome, radiation treatment to the head and neck, and HIV-related salivary gland disease. Xerostomia can also be a side effect of some medications and may be associated with aging.

"The data from this study are promising, given the low incidence of adverse events at potentially therapeutic doses for treating CIAS," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "In addition, the data not only confirm earlier findings that NGX267 increases salivary flow, but also demonstrates that the effect is seen at multiple dose levels and maintained after repetitive dosing. Moving forward, we now have data that suggests that this well-tolerated product candidate could be effective in treating not only CIAS, but also xerostomia. In addition to our planned Phase II study in CIAS, we will consider initiating a small proof of concept study for xerostomia early next year."

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Today the U.S. Food and Drug Administration (FDA) announced ... serogroup B meningococcal disease in individuals ages ... received FDA approval in October, represent a significant step ... "I have heard over and over from parents ...
(Date:1/23/2015)... DES MOINES, Iowa , Jan. 23, 2015  The Partnership to ... Iowa health care leaders and a new study ... prescription medications. The PFCD is a nationwide coalition working to educate ... The research released at the Capitol was focused on how the ...
(Date:1/23/2015)... than a third of reproductive-aged women enrolled in Medicaid, and ... a prescription for an opioid pain medication each year during ... Mortality Weekly Report (MMWR). Opioids are typically ... pain.  They are also found in some prescription cough medications. ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... May 11 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain,Drugstore Ltd. (NYSE: ... China based on the number of directly operated stores,announced today that ... financial results to Tuesday, May 18, 2010 , before,market open. , ... The ...
... SHANGHAI, China , May 11 /PRNewswire-Asia/ -- ... research and development outsourcing company serving the,pharmaceutical, biotechnology, and medical ... United States , today announced its financial results for,first-quarter 2010. ... Highlights, -- First-Quarter 2010 ...
Cached Medicine Technology:China Nepstar Chain Drugstore Reschedules First Quarter 2010 Results to May 18 2China Nepstar Chain Drugstore Reschedules First Quarter 2010 Results to May 18 3WuXi PharmaTech Announces First-Quarter 2010 Results 2WuXi PharmaTech Announces First-Quarter 2010 Results 3WuXi PharmaTech Announces First-Quarter 2010 Results 4WuXi PharmaTech Announces First-Quarter 2010 Results 5WuXi PharmaTech Announces First-Quarter 2010 Results 6WuXi PharmaTech Announces First-Quarter 2010 Results 7WuXi PharmaTech Announces First-Quarter 2010 Results 8WuXi PharmaTech Announces First-Quarter 2010 Results 9WuXi PharmaTech Announces First-Quarter 2010 Results 10WuXi PharmaTech Announces First-Quarter 2010 Results 11WuXi PharmaTech Announces First-Quarter 2010 Results 12WuXi PharmaTech Announces First-Quarter 2010 Results 13WuXi PharmaTech Announces First-Quarter 2010 Results 14WuXi PharmaTech Announces First-Quarter 2010 Results 15WuXi PharmaTech Announces First-Quarter 2010 Results 16
(Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Gabe’s Chemo Duck Program ... App, the first app ever created for kids with cancer. The ... phones and devices, is filled with enjoyable games to help children ... treatments. The free app helps to keep kids entertained, educated and ...
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... ... oral ingestion, and this is known to cause jitters and crashing effects. Now there,s a new ... pepper. Spray Awake is the world,s first personal energy spray to use capsaicin as a way ... ...
... 6 CEL-SCI Corporation (NYSE Amex: CVM ), a ... of infectious diseases and a late-stage oncology company, announced today ... School of Medicine (Johns Hopkins) has given clearance for the ... Johns Hopkins will host the study, which will be led ...
... Calif., Nov. 6 California American Water has designated the ... Drain" week for its Sacramento service area as part of ... toward the common mission of reducing pharmaceutical pollution in our ... household items free of charge at: , , ...
... ... the American Heart Association for the Start! Fit-Friendly Companies Award. , ... Covington, LA (PRWEB) November 6, 2009 ... award winning approach to health and lifestyle management and was recently honored with Platinum-Level ...
... CAMBRIDGE, Mass., Nov. 5 ETEX Corporation, an ... with Alphatec Spine, of Carlsbad, California. Alphatec Spine ... substitute portfolio on a non-exclusive basis in the ... http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO ) , Initial sales and ...
... ELA association and Zinedine Zidane, its emblematic ambassador, are ... regaring the gene therapy in adrenoleukodystrophy conducted in France ... Two children have been treated and their diseases have ... unexpected for a disease destroying the brain in a ...
Cached Medicine News:Health News:New Energy Spray Uses Capsaicin to Deliver Caffeine for Sustained Mental Focus 2Health News:CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine 2Health News:CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine 3Health News:California American Water Celebrates 'No Drugs Down the Drain' Week in Sacramento 2Health News:Gilsbar is Sole Louisiana Company to Win National Award from the American Heart Association 2Health News:ETEX Corporation Announces Distribution Agreement with Alphatec Spine 2Health News:ETEX Corporation Announces Distribution Agreement with Alphatec Spine 3Health News:2 children suffering from adrenoleukodystrophy saved thanks to the ELA Association 2Health News:2 children suffering from adrenoleukodystrophy saved thanks to the ELA Association 3Health News:2 children suffering from adrenoleukodystrophy saved thanks to the ELA Association 4
... drape sheets with a low-profile, roomy ... the operative site during arthroscopic surgery. ... ports for drainage. , ,The ... a standard pack, or in custom ...
The Quantum II Dual Wavelength Analyzer measures differential absorbances of liquid samples and converts those readings into analytical values....
... The ABBOTT PRISM is a fully ... enhance the safety of the blood supply. ... blood supply, it is tested for evidence ... disease. This screening process involves numerous assays, ...
... The First Consolidated Workstation to Automate ... Slide Staining,Now you can perform deparaffinization, ... and routine slide washing with a ... using preprogrammed Vysis protocols for fluorescence ...
Medicine Products: